Skip to content

Xing-Ming Wang

4 papers in the library · 61 citations · publishing 2022-2025

Papers

Sort Most recent Most cited

Esketamine prevents postoperative sleep disturbance in patients with preoperative sleep disorders: a role for oral microbiota.

Translational Psychiatry November 24, 2025 Xin-Yu Li, Di Qiu, Ni Du et al. 1 citation

Patients with preexisting sleep disorders face a significantly increased risk of postoperative sleep disturbance (PSD) due to heightened sensitivity to surgical stress, anesthesia, and hospital-related environmental factors. There is a critical unmet need for effective prophylactic medications to prevent PSD, as current treatment options are limited and often inadequate. This study investigated...

Transforming growth factor-β1 mediates the beneficial effects of arketamine on demyelination and remyelination in the brains of cuprizone-treated mice.

European Journal of Pharmacology December 15, 2024 Ming-Ming Zhao, Ting-Ting Zhu, Dan Xu et al. 14 citations

The novel antidepressant arketamine, the (R)-enantiomer of ketamine, has been shown to ameliorate demyelination and facilitate remyelination in the brains of cuprizone (CPZ)-treated mice. However, the mechanisms behind its effects remain unclear. Given the role of transforming growth factor β1 (TGF-β1) in arketamine's antidepressant-like effects, we examined whether TGF-β1 also plays a role in...

Efficacy and safety of perioperative application of ketamine on postoperative depression: A meta-analysis of randomized controlled studies

Molecular Psychiatry January 20, 2023 Jie Guo, Di Qiu, Han-Wen Gu et al. 46 citations

Ketamine, a commonly used general anesthetic, can produce rapid and sustained antidepressant effect. However, the efficacy and safety of the perioperative application of ketamine on postoperative depression remains uncertain. We performed a meta-analysis to determine the effect of perioperative intravenous administration of ketamine on postoperative depression. Randomized controlled trials...

A role of GABAA receptor α1 subunit in the hippocampus for rapid-acting antidepressant-like effects of ketamine.

Neuropharmacology December 21, 2022 Xiao-Hui Tang, Y. Diao, Zhuoying Ren et al.

Ketamine can produce rapid-acting antidepressant effects in treatment-resistant patients with depression. Although alterations in glutamatergic and GABAergic neurotransmission in the brain play a role in depression, the precise molecular mechanisms in these neurotransmission underlying ketamine's antidepressant actions remain largely unknown. Mice exposed to FSS (forced swimming stress) showed...